viimane versioon :
19/11/2024
Infostab
ingredientide nimekiri
nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
uurimisrühmad
valistab
plakat
Sidemed
sponsorid
Autor
Kasutusjuhend
ajakiri
Caffeine citrate
keemiline struktuur
Kaubanduslikud nimed erinevates maades
Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist
Cafcit
Ameerika ühendriigid
Cafeina 25% Bioquim
Argentiina
Cafeina citrato
Hispaania
Cafeina Fada
Argentiina
Cafeine citrate Biomed
uus-Meremaa
Cafeine Sterop
Belgia
Cafeinnova
Kolumbia
Caffeinospire
Egiptus
Cafirate
India
Citrate de caféine Cooper
Prantsusmaa
Peyona oral y para perfusion
Hispaania
Peyona oral/parenteral
Rumeenia, Saksamaa, Türgi
Viited : Caffeine citrate
tüüp
avaldamine
43
ajaleht
Fraser BD, Berod T, Whitney HAK.
Stability of caffeine citrate injection in polypropylene syringes at room temperature.
Am J Health-Syst Pharm 1997 ; 54: 1106-1108.
318
ajaleht
Donnelly RF, Tirona RG.
Stability of citrated caffeine injectable solution in glass vials.
Am J Hosp Pharm 1994 ; 51: 512-514.
691
ajaleht
Nahata MC, Zingarelli JR, Durell DE.
Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions.
J Clin Pharm Ther 1989 ; 14: 53-55.
1802
ajaleht
Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
2087
ajaleht
Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
3379
ajaleht
Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524.
3644
Labor
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3976
ajaleht
Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4319
ajaleht
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4389
ajaleht
Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4419
ajaleht
Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4543
ajaleht
Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4603
ajaleht
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4742
ajaleht
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.
4837
ajaleht
De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T.
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Eur J Clin Pharmacol 2024 ; 80:1079–1087.
Mentions Légales